WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On March16, 2017, WAVE Life Sciences Ltd. (the Company) announced
its financial results for the quarter and year ended December31,
2016.The full text of the press release issued in connection with
the announcement is furnished as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated by reference herein.
The information in this Current Report on Form 8-K, including
Exhibit 99.1 attached hereto, is intended to be furnished and
shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such
filing.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibit relating to Item 2.02 of this Current
Report on Form 8-Kshall be deemed to be furnishedand not filed:
|
Exhibit No. |
Description |
|
| 99.1 | Press release issued on March16, 2017 |
About WAVE LIFE SCIENCES LTD. (NASDAQ:WVE)
WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington’s disease, duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease, it has programs that target HTT SNP-1 and HTT SNP-2; in DMD, it targets Exon 51, and in IBD, it targets SMAD7. It has selected lead product candidates in its programs targeting HTT SNP-1 and Exon 51. It has late-stage discovery programs in epidermolysis bullosa simplex, in which it targets KRT14 SNP-1 and KRT14 SNP-2, and in DMD, in which it is focused on an additional DMD target, AcRIIb. WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Recent Trading Information
WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) closed its last trading session 00.00 at 27.00 with 87,767 shares trading hands.
